BREAKING NEWS
Search
televisa-iusacell

Most Active Buzz: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), VIVUS, Inc. (NASDAQ:VVUS), Dendreon Corporation (NASDAQ:DNDN)

Idenix Pharmaceuticals Inc (NASDAQ:IDIX)’s shares declined 0.41% to $24. The securities litigation law firm of Brower Piven, A Professional Corporation, on June 16 has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals, Inc. (IDIX) and other violations of state law by the board of directors of Merck & Co., Inc. (“Merck”), in a transaction valued at approximately $3.85 billion. Under the terms of the transaction, shareholders of Idenix would receive $24.50 in cash for each share of Idenix they own.

Get the Inside Scoop On IDIX here with this Free Report

VIVUS, Inc. (NASDAQ:VVUS)’s shares dropped 2.64% to $4.79. The company on June 12 announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.

You won’t believe what we found out about VVUS

The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Qsymia® (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents 7,056,890, 7,553,818, 7,659,256, 7,674,776, 8,580,298, and 8,580,299, which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. VIVUS filed the lawsuit on the basis that Actavis’s proposed generic products infringe each of these patents held by VIVUS.

Dendreon Corporation (NASDAQ:DNDN)’s shares gained 0.44% to $2.28. The company on June 9 announced that John H. Johnson has informed the Board of Directors of his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson has resigned from the Board, effective June 3, 2014, and the Board has elected Douglas G. Watson, Dendreon’s lead independent director, as chairman of the Board. Dendreon’s Board is working with an executive search firm to help identify Mr. Johnson’s successor.

Why Should You Buy DNDN Now? Get The Free Trend Analysis Here




Joe Dashiell was raised in the Twin Cities and is a graduate of the University of St. Thomas. During his free time, he enjoys volunteering and being with friends and family. He is an avid fan of movies and loves to write, shoot, and edit them in his spare time. He is also a musician at heart and plays piano and guitar. He began his journalism career when he was 15-years-old. He and a group of friends competed in NASA's Student Journalism Competition. After winning the National 1st Prize, they were flown out to the Johnson Space Center in Houston Texas to present their project. Shortly afterwards he realized that he wanted to be a journalist.